At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 90 enrolled
Drug / intervention
Vorapaxar 2.5 mg +3 moredrug
Likely dose
Vorapaxar 2.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of SCH 530348 in Subjects With Cerebral Infarction
In Brief
A Phase 2 clinical trial evaluating Vorapaxar 2.5 mg, Vorapaxar 1 mg, and 2 other interventions for Cerebral Infarction. Completed, enrolled 90 participants.
Detailed Summary
The study is designed to assess safety of Vorapaxar when added to standard of care (aspirin) in Japanese subjects with cerebral infarction. The study will assess incidence and tolerability of bleeding, major adverse cardiac events, all adverse events, and effect on expression of markers of inflammation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCerebral Infarction
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2006
Primary CompletionNov 2007
First PostedMay 2008
TodayJul 2026
First PostedMay 26, 2008
Enrollment StartSep 21, 2006
Primary CompletionNov 8, 2007
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 18.1 years ago
Interventions
Vorapaxar 2.5 mgdrug
Oral tablets; once daily for 60 days.
Vorapaxar 1 mgdrug
Oral tablets; once daily for 60 days
Placebodrug
oral tablets; once daily for 60 days
Aspirin 75-150 mgdrug
oral tablets; once daily for 60 days